AGN Share Price Performance
Recent AGN News & Updates
No updates
Algernon Pharmaceuticals Inc. Key Details
Last Reported Earnings
Feb 28, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.0079
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Algernon Pharmaceuticals Inc. Competitors
About AGN
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Canadian Market Performance
- 7 Days: 0.9%
- 3 Months: 11.7%
- 1 Year: 17.4%
- Year to Date: 10.1%
The Consumer Staples sector gained 3.6% while the market remained flat over the last week. Meanwhile, the market is actually up 17% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
